You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Moodys
AstraZeneca
Express Scripts
Merck

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 9,410,159

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,410,159
Title:Chimeric promoters capable of mediating gene expression in plants upon pathogen infection and uses thereof
Abstract: Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.
Inventor(s): Kirsch; Christoph (Cologne, DE), Logemann; Elke (Pulheim-Dansweiler, DE), Hahlbrock; Klaus (Freiburg, DE), Rushton; Paul (Brookings, SD), Somssich; Imre (Cologne, DE)
Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (Berlin, DE)
Application Number:13/930,387
Patent Claims:see list of patent claims

Details for Patent 9,410,159

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (Berlin, DE) 2018-11-12 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (Berlin, DE) 2018-11-12 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (Berlin, DE) 2018-11-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Baxter
Mallinckrodt
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.